GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Inventory Turnover

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Inventory Turnover : 0.34 (As of Jun. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Paratek Pharmaceuticals's Cost of Goods Sold for the three months ended in Jun. 2023 was $4.4 Mil. Paratek Pharmaceuticals's Average Total Inventories for the quarter that ended in Jun. 2023 was $12.7 Mil. Paratek Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2023 was 0.34.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Paratek Pharmaceuticals's Days Inventory for the three months ended in Jun. 2023 was 265.33.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Paratek Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Jun. 2023 was 0.33.


Paratek Pharmaceuticals Inventory Turnover Historical Data

The historical data trend for Paratek Pharmaceuticals's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Inventory Turnover Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.57 0.66 1.68 1.67

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.26 0.55 0.41 0.34

Paratek Pharmaceuticals Inventory Turnover Calculation

Paratek Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Inventory Turnover (A: Dec. 2022 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2022 ) / ((Total Inventories (A: Dec. 2021 ) + Total Inventories (A: Dec. 2022 )) / count )
=23.056 / ((11.02 + 16.565) / 2 )
=23.056 / 13.7925
=1.67

Paratek Pharmaceuticals's Inventory Turnover for the quarter that ended in Jun. 2023 is calculated as

Inventory Turnover (Q: Jun. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Jun. 2023 ) / ((Total Inventories (Q: Mar. 2023 ) + Total Inventories (Q: Jun. 2023 )) / count )
=4.368 / ((13.989 + 11.413) / 2 )
=4.368 / 12.701
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paratek Pharmaceuticals  (NAS:PRTK) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Paratek Pharmaceuticals's Days Inventory for the three months ended in Jun. 2023 is calculated as:

Days Inventory =Average Total Inventories (Q: Jun. 2023 )/Cost of Goods Sold (Q: Jun. 2023 )*Days in Period
=12.701/4.368*365 / 4
=265.33

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Paratek Pharmaceuticals's Inventory to Revenue for the quarter that ended in Jun. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=12.701 / 38.062
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Paratek Pharmaceuticals Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Executives
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh director, officer: CEO 75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel officer: CLO, General Counsel & Sec. ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow officer: President & Chief Commercial C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner officer: Chief Development & Regulatory C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann director LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham director, officer: Exec. Chairman of the Board 890 WINTER STREET, WALTHAM MA 02451
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan officer: Chief Financial Officer 75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Headlines

From GuruFocus